{
  "id": 11073545,
  "title": "Lipocine director John Higuchi buys $27,131 in company stock",
  "url": "https://urgent.news/2026/10/01/lipocine-director-john-higuchi-buys-27-131-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T01:01:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/lipocine-director-john-higuchi-buys-27131-in-company-stock-93CH-4926153"
  },
  "original_language": "en",
  "account": null,
  "summary": "Director John Higuchi of Lipocine Inc. (LPCN) made a move in the stock market by purchasing 12,561 shares of the company's common stock on September 28, 2026, for a total of $27,131. This transaction, reported in a Form 4 filing with the Securities and Exchange Commission, occurred at a price of $2.16 per share, a figure that reflects the stock's current valuation near its 52-week low of $1.81, marking a 76% decrease over the past six months. Despite the recent downturn, InvestingPro analysis suggests that Lipocine is undervalued, with a Fair Value estimate of $2.97 per share. Following this acquisition, Higuchi's beneficial ownership of Lipocine common stock has increased to 216,358 shares. The company's financial health is noted as robust, with more cash than debt on its balance sheet, and analysts predict profitability for the current year. Additionally, Lipocine has embarked on a Phase 3 clinical trial for LPCN1154, targeting severe postpartum depression, and has updated its sales agent fee agreement with A.G.P./Alliance Global Partners, maintaining a Neutral rating and a $4 price target from H.C. Wainwright.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}